Legacy Wealth Asset Management LLC Trims Position in Lantheus Holdings, Inc. (NASDAQ:LNTH)

Legacy Wealth Asset Management LLC decreased its holdings in shares of Lantheus Holdings, Inc. (NASDAQ:LNTH) by 9.4% in the 3rd quarter, Holdings Channel.com reports. The institutional investor owned 9,139 shares of the medical equipment provider’s stock after selling 944 shares during the quarter. Legacy Wealth Asset Management LLC’s holdings in Lantheus were worth $1,003,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors have also recently made changes to their positions in LNTH. Signaturefd LLC lifted its position in Lantheus by 40.5% during the 3rd quarter. Signaturefd LLC now owns 319 shares of the medical equipment provider’s stock worth $35,000 after acquiring an additional 92 shares during the period. GAMMA Investing LLC lifted its holdings in shares of Lantheus by 184.1% during the second quarter. GAMMA Investing LLC now owns 321 shares of the medical equipment provider’s stock worth $26,000 after purchasing an additional 208 shares during the period. UMB Bank n.a. grew its position in Lantheus by 42.1% in the 3rd quarter. UMB Bank n.a. now owns 425 shares of the medical equipment provider’s stock valued at $47,000 after buying an additional 126 shares during the last quarter. Kathleen S. Wright Associates Inc. acquired a new position in Lantheus in the 3rd quarter valued at $51,000. Finally, Fidelis Capital Partners LLC purchased a new position in Lantheus during the 1st quarter worth $34,000. Hedge funds and other institutional investors own 99.06% of the company’s stock.

Insider Transactions at Lantheus

In other Lantheus news, Director Mary Anne Heino sold 10,481 shares of the stock in a transaction on Friday, August 2nd. The stock was sold at an average price of $95.50, for a total transaction of $1,000,935.50. Following the sale, the director now owns 454,923 shares in the company, valued at approximately $43,445,146.50. This represents a 0.00 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. In other Lantheus news, Director Gerard Ber sold 15,500 shares of the company’s stock in a transaction dated Monday, August 12th. The shares were sold at an average price of $96.48, for a total value of $1,495,440.00. Following the transaction, the director now directly owns 21,221 shares in the company, valued at approximately $2,047,402.08. This represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Director Mary Anne Heino sold 10,481 shares of the firm’s stock in a transaction dated Friday, August 2nd. The stock was sold at an average price of $95.50, for a total transaction of $1,000,935.50. Following the sale, the director now directly owns 454,923 shares in the company, valued at $43,445,146.50. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 27,981 shares of company stock valued at $2,689,156 in the last ninety days. Corporate insiders own 1.50% of the company’s stock.

Analyst Ratings Changes

A number of research analysts have recently issued reports on the stock. Leerink Partners boosted their price target on shares of Lantheus from $106.00 to $127.00 and gave the stock an “outperform” rating in a research note on Thursday, July 11th. Redburn Atlantic started coverage on Lantheus in a research report on Tuesday, September 3rd. They set a “buy” rating and a $175.00 target price on the stock. JMP Securities reduced their price target on Lantheus from $130.00 to $125.00 and set a “market outperform” rating for the company in a report on Thursday, August 1st. B. Riley upped their price objective on Lantheus from $105.00 to $146.00 and gave the stock a “buy” rating in a report on Thursday, July 25th. Finally, Truist Financial decreased their target price on shares of Lantheus from $141.00 to $135.00 and set a “buy” rating on the stock in a research report on Thursday, August 1st. Two equities research analysts have rated the stock with a hold rating and eight have given a buy rating to the company. According to MarketBeat, Lantheus presently has an average rating of “Moderate Buy” and a consensus price target of $126.00.

Lantheus Stock Up 0.4 %

Lantheus stock opened at $110.30 on Friday. Lantheus Holdings, Inc. has a fifty-two week low of $50.20 and a fifty-two week high of $126.89. The firm has a market capitalization of $7.66 billion, a price-to-earnings ratio of 18.08 and a beta of 0.50. The stock’s fifty day moving average is $107.32 and its two-hundred day moving average is $92.71. The company has a debt-to-equity ratio of 0.55, a quick ratio of 4.41 and a current ratio of 4.68.

Lantheus (NASDAQ:LNTH) last issued its quarterly earnings data on Wednesday, July 31st. The medical equipment provider reported $1.61 EPS for the quarter, missing analysts’ consensus estimates of $1.68 by ($0.07). The business had revenue of $394.10 million during the quarter, compared to analyst estimates of $382.12 million. Lantheus had a net margin of 29.80% and a return on equity of 48.36%. Lantheus’s revenue was up 22.5% on a year-over-year basis. During the same period in the previous year, the company posted $1.40 earnings per share. Analysts predict that Lantheus Holdings, Inc. will post 5.99 EPS for the current fiscal year.

About Lantheus

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.